{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:13:43Z","timestamp":1786979623487,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00115-019-00825-8","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T03:02:48Z","timestamp":1574823768000},"page":"1279-1291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Parkinson-Syndrome bei geriatrischen Patienten","Parkinson\u2019s syndromes in geriatric patients"],"prefix":"10.1007","volume":"90","author":[{"given":"K.","family":"Amadori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,27]]},"reference":[{"issue":"100","key":"825_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.arr.2014.01.004","volume":"14","author":"A Reeve","year":"2014","unstructured":"Reeve\u00a0A, Simcox\u00a0E, Turnbull\u00a0D (2014) Ageing and parkinson\u2019s disease: why is advancing age the biggest risk factor? Ageing Res Rev 14(100):19\u201330","journal-title":"Ageing Res Rev"},{"issue":"11","key":"825_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"GBD 2016 Parkinson\u2019s Disease Collaborators","year":"2018","unstructured":"GBD 2016 Parkinson\u2019s Disease Collaborators (2018) Global, regional, and national burden of parkinson\u2019s disease, 1990\u20132016: a\u00a0systematic analysis for the global burden of disease study 2016. Lancet Neurol 17(11):939\u2013953","journal-title":"Lancet Neurol"},{"issue":"2","key":"825_CR3","first-page":"69","volume":"15","author":"S Klebe","year":"2014","unstructured":"Klebe\u00a0S (2014) Sekund\u00e4re Parkinson-Syndrome. J\u00a0Neurol Neurochir Psychiatr 15(2):69\u201375","journal-title":"J Neurol Neurochir Psychiatr"},{"issue":"3","key":"825_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/mds.10362","volume":"18","author":"J Benito-Le\u00f3n","year":"2003","unstructured":"Benito-Le\u00f3n\u00a0J, Bermejo-Pareja\u00a0F, Rodr\u00edguez\u00a0J, Molina\u00a0JA, Gabriel\u00a0R, Morales\u00a0JM, Neurological Disorders in Central Spain (NEDICES) Study Group (2003) Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord 18(3):267\u2013274","journal-title":"Mov Disord"},{"key":"825_CR5","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S1474-4422(05)70226-X","volume":"4","author":"GK Wenning","year":"2005","unstructured":"Wenning\u00a0GK, Kiechl\u00a0S, Seppi\u00a0K, M\u00fcller\u00a0J, H\u00f6gl\u00a0B, Saletu\u00a0M, Rungger\u00a0G, Gasperi\u00a0A, Willeit\u00a0J, Poewe\u00a0W (2005) Prevalence of movement disorders in men and women aged 50\u201389 years (bruneck study cohort): a\u00a0population-based study. Lancet Neurol 4:815\u2013820","journal-title":"Lancet Neurol"},{"issue":"6","key":"825_CR6","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/mds.20806","volume":"21","author":"MT Barbosa","year":"2006","unstructured":"Barbosa\u00a0MT, Caramelli\u00a0P, Maia\u00a0DP, Cunningham\u00a0MC, Guerra\u00a0HL, Lima-Costa\u00a0MF, Cardoso\u00a0F (2006) Parkinsonism and parkinson\u2019s disease in the elderly: a\u00a0community-based survey in Brazil (the bambu\u00ed study). Mov Disord 21(6):800\u2013808","journal-title":"Mov Disord"},{"issue":"10","key":"825_CR7","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/mds.20527","volume":"20","author":"D Aarsland","year":"2005","unstructured":"Aarsland\u00a0D, Zaccai\u00a0J, Brayne\u00a0C (2005) A systematic review of prevalence studies of dementia in parkinson\u2019s disease. Mov Disord 20(10):1255\u20131263","journal-title":"Mov Disord"},{"issue":"1\u20132","key":"825_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jns.2009.08.034","volume":"289","author":"D Aarsland","year":"2010","unstructured":"Aarsland\u00a0D, Kurz\u00a0MW (2010) The epidemiology of dementia associated with parkinson disease. J\u00a0Neurol Sci 289(1\u20132):18\u201322","journal-title":"J Neurol Sci"},{"issue":"1","key":"825_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00415-006-0234-8","volume":"254","author":"D Aarsland","year":"2007","unstructured":"Aarsland\u00a0D, Kvaloy\u00a0JT, Andersen\u00a0K, Larsen\u00a0JP, Tang\u00a0MX, Lolk\u00a0A, Kragh-S\u00f6rensen\u00a0P, Marder\u00a0K (2007) The effect of age of onset of PD on risk of dementia. J\u00a0Neurol 254(1):38\u201345","journal-title":"J Neurol"},{"key":"825_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40035-016-0058-0","volume":"5","author":"Y Xu","year":"2016","unstructured":"Xu\u00a0Y, Yang\u00a0J, Shang\u00a0H (2016) meta-analysis of risk factors for parkinson\u2019s disease dementia. Transl Neurodegener 5:11","journal-title":"Transl Neurodegener"},{"issue":"12","key":"825_CR11","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma\u00a0RB, Berg\u00a0D, Stern\u00a0M, Poewe\u00a0W, Olanow\u00a0CW, Oertel\u00a0W, Obeso\u00a0J, Marek\u00a0K, Litvan\u00a0I, Lang\u00a0AE, Halliday\u00a0G, Goetz\u00a0CG, Gasser\u00a0T, Dubois\u00a0B, Chan\u00a0P, Bloem\u00a0BR, Adler\u00a0CH, Deuschl\u00a0G (2015) MDS clinical diagnostic criteria for parkinson\u2019s disease. Mov Disord 30(12):1591\u20131601","journal-title":"Mov Disord"},{"issue":"7","key":"825_CR12","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.parkreldis.2008.12.005","volume":"15","author":"A Haehner","year":"2009","unstructured":"Haehner\u00a0A, Boesveldt\u00a0S, Berendse\u00a0HW, Mackay-Sim\u00a0A, Fleischmann\u00a0J, Silburn\u00a0PA, Johnston\u00a0AN, Mellick\u00a0GD, Herting\u00a0B, Reichmann\u00a0H, Hummel\u00a0T (2009) Prevalence of smell loss in parkinson\u2019s disease\u2014a multicenter study. Parkinsonism Relat Disord 15(7):490\u2013494","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"825_CR13","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/mds.27018","volume":"32","author":"EK St Louis","year":"2017","unstructured":"St Louis\u00a0EK, Boeve\u00a0AR, Boeve\u00a0BF (2017) REM sleep behavior disorder in parkinson\u2019s disease and other synucleinopathies. Mov Disord 32(5):645\u2013658","journal-title":"Mov Disord"},{"issue":"3","key":"825_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/mds.21854","volume":"23","author":"CD Esper","year":"2008","unstructured":"Esper\u00a0CD, Factor\u00a0SA (2008) Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord 23(3):401\u2013404","journal-title":"Mov Disord"},{"issue":"1","key":"825_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3988\/jcn.2012.8.1.15","volume":"8","author":"HW Shin","year":"2012","unstructured":"Shin\u00a0HW, Chung\u00a0SJ (2012) Drug-induced parkinsonism. J\u00a0Clin Neurol 8(1):15\u201321","journal-title":"J Clin Neurol"},{"key":"825_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3389\/fneur.2017.00481","volume":"8","author":"A Miguel-Puga","year":"2017","unstructured":"Miguel-Puga\u00a0A, Villafuerte\u00a0G, Salas-Pacheco\u00a0J, Arias-Carrion\u00a0O (2017) Therapeutic interventions for vascular parkinsonism: a systematic review and meta-analysis. Front Neurol 8:481","journal-title":"Front Neurol"},{"key":"825_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1471-2377-7-27","volume":"7","author":"AM Vlaar","year":"2007","unstructured":"Vlaar\u00a0AM, van Kroonenburgh\u00a0MJ, Kessels\u00a0AG, Weber\u00a0WE (2007) Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol 7:27","journal-title":"BMC Neurol"},{"issue":"9","key":"825_CR18","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/mds.21479","volume":"22","author":"J Zijlmans","year":"2007","unstructured":"Zijlmans\u00a0J, Evans\u00a0A, Fontes\u00a0F, Katzenschlager\u00a0R, Gacinovic\u00a0S, Lees\u00a0AJ, Costa\u00a0D (2007) (123I) FP-CIT spect study in vascular parkinsonism and parkinson\u2019s disease. Mov Disord 22(9):1278\u20131285","journal-title":"Mov Disord"},{"key":"825_CR19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","volume":"39","author":"D Podsiadlo","year":"1991","unstructured":"Podsiadlo\u00a0D, Richardson\u00a0S (1991) The timed \u201eup & go\u201c: a\u00a0test of basic functional mobility for frail elderly persons. J\u00a0Am Geriatr Soc 39:142\u2013148","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"825_CR20","doi-asserted-by":"publisher","first-page":"M221","DOI":"10.1093\/gerona\/55.4.M221","volume":"55","author":"JM Guralnik","year":"2000","unstructured":"Guralnik\u00a0JM, Ferrucci\u00a0L, Pieper\u00a0CF, Leveille\u00a0SG, Markides\u00a0KS, Ostir\u00a0GV, Studenski\u00a0S, Berkman\u00a0LF, Wallace\u00a0RB (2000) Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J\u00a0Gerontol A Biol Sci Med Sci 55(4):M221\u201331","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"825_CR21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0140-6736(97)24009-2","volume":"349","author":"L Lundin-Olsson","year":"1997","unstructured":"Lundin-Olsson\u00a0L, Nyberg\u00a0L, Gustafson\u00a0Y (1997) \u201eStops walking when talking\u201c as a\u00a0predictor of falls in elderly people. Lancet 349:617","journal-title":"Lancet"},{"key":"825_CR22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/mds.21720","volume":"23","author":"G Yogev-Seligmann","year":"2008","unstructured":"Yogev-Seligmann\u00a0G, Hausdorff\u00a0JM, Giladi\u00a0N (2008) The role of executive function and attention in gait. Mov Disord 23:329\u2013342","journal-title":"Mov Disord"},{"key":"825_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00391-014-0854-z","volume":"48","author":"S Krupp","year":"2015","unstructured":"Krupp\u00a0S, Kasper\u00a0J, Balck\u00a0F, Schnoor\u00a0M, Eisemann\u00a0N, Lohse\u00a0K, Brunk\u00a0J, Katalinic\u00a0A, Willkomm\u00a0M (2015) \u201etimed up and go\u201c f\u00fcr die finger in form des 20-cents-tests: Psychometrische G\u00fctekriterien eines einfachen Feinmotorik-performance-tests. Z\u00a0Gerontol Geriatr 48:121\u2013127","journal-title":"Z Gerontol Geriatr"},{"key":"825_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein\u00a0MF, Folstein\u00a0SE, Mc Mugh\u00a0PR (1975) \u201eMini-mental state\u201c: a\u00a0practical method for grading the cognitive state of patients for the clinician. J\u00a0Psychiatr Res 12:189\u2013198","journal-title":"J Psychiatr Res"},{"issue":"4","key":"825_CR25","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine\u00a0ZS, Phillips\u00a0NA, B\u00e9dirian\u00a0V, Charbonneau\u00a0S, Whitehead\u00a0V, Collin\u00a0I, Cummings\u00a0JL, Chertkow\u00a0H (2005) The montreal cognitive assessment, MoCA: a\u00a0brief screening tool for mild cognitive impairment. J\u00a0Am Geriatr Soc 53(4):695\u2013699","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"825_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.parkreldis.2007.06.008","volume":"14","author":"E Kalbe","year":"2008","unstructured":"Kalbe\u00a0E, Calabrese\u00a0P, Kohn\u00a0N, Hilker\u00a0R, Riedel\u00a0O, Wittchen\u00a0H\u2011U, Dodel\u00a0R, Otto\u00a0J, Ebersbach\u00a0G, Kessler\u00a0J (2008) Screening for cognitive deficits in parkinson\u2019s disease with the parkinson neuropsychometric dementia assessment (PANDA) instrument. Parkinsonism Relat Disord 14(2):93\u2013101","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"825_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0022-3956(82)90033-4","volume":"17","author":"JA Yesavage","year":"1982","unstructured":"Yesavage\u00a0JA, Brink\u00a0TL, Rose\u00a0TL, Lum\u00a0O, Huang\u00a0V, Adey\u00a0M, Leirer\u00a0VO (1982\u20131983) Development and validation of a\u00a0geriatric depression screening scale: a\u00a0preliminary report. J\u00a0Psychiatr Res 17(1):37\u201349","journal-title":"J Psychiatr Res"},{"key":"825_CR28","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1055\/s-2007-1017628","volume":"26","author":"K Berger","year":"1999","unstructured":"Berger\u00a0K, Broll\u00a0S, Winkelmann\u00a0J, Heberlein\u00a0I, M\u00fcller\u00a0T, Ries\u00a0V (1999) Untersuchung zur Reliabilit\u00e4t der deutschen Version des PDQ-39: Ein krankheitsspezifischer Fragebogen zur Erfassung der Lebensqualit\u00e4t von Parkinson-Patienten. Akt Neurol 26:180\u2013184","journal-title":"Akt Neurol"},{"key":"825_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1056\/NEJMoa1809983","volume":"380","author":"CVM Verschuur","year":"2019","unstructured":"Verschuur\u00a0CVM, Suwijn\u00a0SR, Boel\u00a0JA, LEAP Study Group, LEAP Study Group (2019) Randomized delayed-start trial of levodopa in parkinson\u2019s disease. N\u00a0Engl J Med 380:315\u2013324","journal-title":"N Engl J Med"},{"issue":"21","key":"825_CR30","doi-asserted-by":"publisher","first-page":"e1849","DOI":"10.1212\/WNL.0000000000005557","volume":"90","author":"JJ Ferreira","year":"2018","unstructured":"Ferreira\u00a0JJ, Lees\u00a0AJ, Poewe\u00a0W, Rascol\u00a0O, Rocha\u00a0JF, Keller\u00a0B, Soares-da Silva\u00a0P (2018) Effectiveness of opicapone and switching from entacapone in fluctuating parkinson disease. Neurology 90(21):e1849\u201357","journal-title":"Neurology"},{"issue":"10","key":"825_CR31","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/mds.25961","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain\u00a0R, Szasz\u00a0J, Stanzione\u00a0P, Meshram\u00a0C, Bhatt\u00a0MH, Chirilineau\u00a0D, Stocchi\u00a0F, Lucini\u00a0V, Giuliani\u00a0R, Forrest\u00a0E, Rice\u00a0P, Anand\u00a0R, Study 018 Investigators (2014) Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late parkinson\u2019s disease. Mov Disord 29(10):1273\u20131280","journal-title":"Mov Disord"},{"issue":"3\u20134","key":"825_CR32","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000492221","volume":"51","author":"AR Qureshi","year":"2018","unstructured":"Qureshi\u00a0AR, Rana\u00a0AQ, Malik\u00a0SH, Rizvi\u00a0SFH, Akhter\u00a0S, Vannabouathong\u00a0C, Sarfraz\u00a0Z, Rana\u00a0R (2018) Comprehensive examination of therapies for pain in parkinson\u2019s disease: a systematic review and meta-analysis. Neuroepidemiology 51(3\u20134):190\u2013206","journal-title":"Neuroepidemiology"},{"issue":"8","key":"825_CR33","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1001\/jamaneurol.2017.0943","volume":"74","author":"R Pahwa","year":"2017","unstructured":"Pahwa\u00a0R, Tanner\u00a0CM, Hauser\u00a0RA, Isaacson\u00a0SH, Nausieda\u00a0PA, Truong\u00a0DD, Agarwal\u00a0P, Hull\u00a0KL, Lyons\u00a0KE, Johnson\u00a0R, Stempien\u00a0MJ (2017) ADS-5102 (amantadine) extended-release capsules for Levodopa-induced dyskinesia in parkinson disease (EASE LID study): a randomized clinical trial. JAMA Neurol 74(8):941\u2013949","journal-title":"JAMA Neurol"},{"key":"825_CR34","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa041470","volume":"351","author":"M Emre","year":"2004","unstructured":"Emre\u00a0M, Aarsland\u00a0D, Albanese\u00a0A et\u00a0al (2004) Rivastigmine for dementia associated with parkinson\u2019s disease. N\u00a0Engl J Med 351:2509\u20132518","journal-title":"N Engl J Med"},{"key":"825_CR35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1474-4422(15)00389-0","volume":"15","author":"EJ Henderson","year":"2016","unstructured":"Henderson\u00a0EJ, Lord\u00a0SR, Brodie\u00a0MA, Gaunt\u00a0DM, Lawrence\u00a0AD, Close\u00a0JCT, Whone\u00a0AL, Ben-Shlomo\u00a0Y (2016) Rivastigmine for gait stability in patients with parkinson\u2019s disease (reSPonD): a\u00a0randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15:249\u2013258","journal-title":"Lancet Neurol"},{"issue":"2","key":"825_CR36","first-page":"144","volume":"23","author":"G Mallien","year":"2017","unstructured":"Mallien\u00a0G, Schroeteler\u00a0FE, Ebersbach\u00a0G (2017) Amplitudenorientierte Therapien beim idiopathischen Parkinson-Syndrom: LSVT LOUD und LSVT BIG. Neurol Rehabil 23(2):144\u2013152","journal-title":"Neurol Rehabil"},{"issue":"4","key":"825_CR37","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1044\/1058-0360(2012\/11-0125)","volume":"21","author":"AE Halpern","year":"2012","unstructured":"Halpern\u00a0AE, Ramig\u00a0LO, Matos\u00a0CE, Petska-Cable\u00a0JA, Spielman\u00a0JL, Pogoda\u00a0JM, Gilley\u00a0PM, Sapir\u00a0S, Bennett\u00a0JK, McFarland\u00a0DH (2012) Innovative technology for the assisted delivery of intensive voice treatment (LSVT LOUD) for parkinson disease. Am J Speech Lang Pathol 21(4):354\u2013367","journal-title":"Am J Speech Lang Pathol"},{"issue":"9","key":"825_CR38","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1177\/0269216313495287","volume":"27","author":"EW Richfield","year":"2013","unstructured":"Richfield\u00a0EW, Jones\u00a0EJS, Alty\u00a0JE (2013) Palliative care for parkinson\u2019s disease: a summary of the evidence and future directions. Palliat Med 27(9):805\u2013810","journal-title":"Palliat Med"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-019-00825-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-019-00825-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-019-00825-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T19:17:58Z","timestamp":1606331878000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-019-00825-8"}},"subtitle":["Epidemiologische, klinische und therapeutische Besonderheiten","Epidemiological, clinical and therapeutic characteristics"],"short-title":[],"issued":{"date-parts":[[2019,11,27]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["825"],"URL":"https:\/\/doi.org\/10.1007\/s00115-019-00825-8","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,27]]},"assertion":[{"value":"27 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>K. Amadori<\/b>: Finanzielle Interessen: Aktien GlaxoSmithKline. Nichtfinanzielle Interessen: Angestellte Klinik\u00e4rztin, Leitende \u00c4rztin der Klinik f\u00fcr Altersmedizin (im Kollegialsystem) und Ober\u00e4rztin der Klinik f\u00fcr Neurologie am Klinikum Frankfurt H\u00f6chst\u00a0| Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Neurologie, Deutsche Gesellschaft f\u00fcr Geriatrie. <b>T. Steiner<\/b>: Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Octapharma (investigatoreninitiierte randomisierte klinische Studie). Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: BMS Pfizer, Bayer, Boehringer, Daiichy Sankyo, Octapharma. Bezahlter Berater\/interner Schulungsreferent\/Gehaltsempf\u00e4nger o.\u202f\u00c4.: BMS Pfizer, Bayer, Boehringer, Octapharma. Patente, Gesch\u00e4ftsanteile, Aktien o.\u202f\u00c4. an einer im Medizinbereich aktiven Firma: NovoNordisk. Nichtfinanzielle Interessen: Angestellter Neurologe und Chefarzt der Neurologischen Klinik, Klinikum Frankfurt H\u00f6chst, Frankfurt\u00a0| Wissenschaftlicher Mitarbeiter der Neurologischen Universit\u00e4tsklinik Heidelberg\u00a0| Vorsitzender der Leitlinienkommission der ESO\u00a0| Mitgliedschaften: ESO, DGN, DSG. WSC, \u201eBoard of Directors\u201c der ESO.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}